- Home
- SHIP vs VTYX Comparison
SHIP vs VTYX Comparison
Compare SHIP & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHIP
- VTYX
- Stock Information
- Founded
- SHIP 2008
- VTYX 2018
- Country
- SHIP Greece
- VTYX United States
- Employees
- SHIP N/A
- VTYX N/A
- Industry
- SHIP Marine Transportation
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SHIP Consumer Discretionary
- VTYX Health Care
- Exchange
- SHIP Nasdaq
- VTYX Nasdaq
- Market Cap
- SHIP 170.5M
- VTYX 184.6M
- IPO Year
- SHIP 2007
- VTYX 2021
- Fundamental
- Price
- SHIP $7.01
- VTYX $2.30
- Analyst Decision
- SHIP Strong Buy
- VTYX Buy
- Analyst Count
- SHIP 2
- VTYX 5
- Target Price
- SHIP $12.50
- VTYX $8.40
- AVG Volume (30 Days)
- SHIP 319.3K
- VTYX 2.3M
- Earning Date
- SHIP 11-05-2024
- VTYX 11-07-2024
- Dividend Yield
- SHIP 14.96%
- VTYX N/A
- EPS Growth
- SHIP N/A
- VTYX N/A
- EPS
- SHIP 2.36
- VTYX N/A
- Revenue
- SHIP $165,210,000.00
- VTYX N/A
- Revenue This Year
- SHIP $52.75
- VTYX N/A
- Revenue Next Year
- SHIP $1.07
- VTYX N/A
- P/E Ratio
- SHIP $2.95
- VTYX N/A
- Revenue Growth
- SHIP 66.32
- VTYX N/A
- 52 Week Low
- SHIP $6.86
- VTYX $1.67
- 52 Week High
- SHIP $13.19
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- SHIP 23.67
- VTYX 47.68
- Support Level
- SHIP $7.29
- VTYX $2.21
- Resistance Level
- SHIP $7.25
- VTYX $2.54
- Average True Range (ATR)
- SHIP 0.26
- VTYX 0.27
- MACD
- SHIP 0.01
- VTYX -0.05
- Stochastic Oscillator
- SHIP 12.96
- VTYX 8.02
About SHIP Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company fleet of vessels includes Fellowship, Championship, Partnership, Knightship, Lordship, Gloriuship, Leadership, Geniuship, Premiership, and Squireship among others.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.